Medicamen Biotech is currently locked at its upper circuit limit of Rs. 16.15, up by 0.75 points or 4.87% from its previous closing of Rs. 15.40 on the BSE.
The scrip opened at Rs. 15.90 and has touched a high and low of Rs. 16.15 and Rs. 15.90 respectively. So far 19287 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 38.10 on 17-Oct-2011 and a 52 week low of Rs. 14.05 on 23-Nov-2011.
Last one week high and low of the scrip stood at Rs. 19.70 and Rs. 15.40 respectively. The current market cap of the company is Rs. 12.15 crore.
The promoters holding in the company stood at 34.84% while Non-Institutions held 65.16%.
Medicamen Biotech has received an ANVISA Brazil approval for Non Beta Lactum solid tablets and coated tablets manufactured at its plant situated at Bhiwadi in Rajasthan vide resolution 5397 No RE of December 02, 2011, officially published in the gazzatte on December 05, 2011 valid for 2 years.
Medicamen Biotech manufactures pharmaceutical formulations for the Indian and overseas markets. Its product range consists of antibiotics, anti-fungicides, anti-diabetics, anti-tuberculosis, tranquillisers, laxatives, anti-asthmatics, and anti-depressants.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1777.65 |
Dr. Reddys Lab | 1194.55 |
Cipla | 1465.65 |
Lupin | 2043.30 |
Zydus Lifesciences | 944.25 |
View more.. |